News
A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo ...
The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.
Eli Lilly announced that its obesity therapy Zepbound delivered superior outcomes versus Novo Nordisk’s Wegovy across five ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results